导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.10% | 1661/4407 |
| 近一周 | -1.44% | 2328/5016 |
| 近一月 | -5.30% | 2130/4972 |
| 近一季 | -7.50% | 2180/4811 |
| 近半年 | -0.52% | 1581/4547 |
| 近一年 | 5.25% | 1438/4077 |
| 近两年 | 59.75% | 1134/2754 |
| 近三年 | 38.72% | 718/2082 |
| 成立以来 | 65.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.52% 2342/4961 |
14.60% 1789/5312 |
- - |
- - |
| 2025 | 24.57% 1784/4813 |
0.37% 1880/3635 |
2.49% 1541/4076 |
19.90% 2082/4524 |
1.00% 1608/4813 |
| 2024 | 15.73% 891/3463 |
1.68% 864/2808 |
-2.13% 1141/3014 |
16.91% 1316/3129 |
-0.52% 1452/3463 |
| 2023 | -6.96% 885/2656 |
5.31% 803/2280 |
-3.93% 974/2385 |
-2.76% 743/2515 |
-5.43% 1352/2655 |
| 2022 | -19.87% 910/2207 |
-13.63% 801/1919 |
5.55% 877/2016 |
-12.73% 771/2113 |
0.71% 1464/2208 |
| 2021 | 1.34% 680/1822 |
-3.03% 743/1255 |
6.01% 773/1330 |
-3.25% 624/1466 |
1.89% 760/1822 |
| 2020 | 40.15% 315/1250 |
-6.24% 473/1028 |
16.60% 429/1067 |
14.35% 282/1164 |
12.12% 500/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 易方达中证800ETF联接C VS. 长安沪深300非周期A(740101) |